"This acquisition is a further step in our strategy to strengthen our position as a complete solution provider in the cell analysis research market," said Dr. Jürgen Schwiezer, CEO Division Roche Diagnostics. "Innovatis' technology will complement the existing Roche cell analysis portfolio and is synergistic to the xCELLigence technology launched in 2008."
Michael Grohmann, CEO of the innovatis AG stated "Roche has been one of our key customers for many years, in particular since the successful development of our cell analysis technology over 10 years ago. The innovatis technology is very well placed for future growth as part of Roche Applied Science."
Innovatis will become a fully-integrated part of Roche Applied Science, a global business area of the Diagnostic Division of Roche. The company will continue to develop and market products for cell analysis through Roche Applied Science's extensive worldwide network. The transaction is expected to be completed within the next few weeks, subject to shareholder approval and regulatory clearance.
About innovatis
In the 1990s, a team of specialists from the scientific and the IT fields in Bielefeld, Germany developed the first fully automated cell counting system. This product soon afterwards revolutionized the market as it replaced manual cell counting in many laboratories in the pharmaceutical industry. The foundation stone was laid for the successful business development of innovatis AG. Today, many years later, this motto still applies to innovatis - the meaning, however, is no longer just applicable to cell counting. In the meantime, innovatis' comprehensive consulting competence counts more to customers than the original product.
For more information about innovatis, please visit the company's website at www.innovatis.com.
Innovatis AG is fully-owned by two private equity funds that are exclusively advised by VENTIZZ Capital Partners Advisory AG ("VENTIZZ"). Close Brothers acted as the exclusive financial advisor to Ventizz Capital Partners on this transaction.